119 related articles for article (PubMed ID: 37703505)
1. Steroid-Dependency in Posner-Schlossman Syndrome: A Suggested Topical 2% Ganciclovir and Gradual Decrement of Topical Steroid Combination Therapy from Shanghai PSS Study.
Ying Y; Sun Y; Sheng Q; Zhai R; Fan X; Kong X
Ocul Immunol Inflamm; 2023 Sep; ():1-7. PubMed ID: 37703505
[TBL] [Abstract][Full Text] [Related]
2. [Effect of 2% ganciclovir eye drops on cytomegalovirus positive Posner-Schlossman syndrome].
Zhai RY; Xu H; Kong XM; Wang ZJ
Zhonghua Yan Ke Za Zhi; 2018 Nov; 54(11):833-838. PubMed ID: 30440154
[No Abstract] [Full Text] [Related]
3. Iris abnormalities may influence the efficacy and filtration strategies of Posner-Schlossman syndrome: a retrospective study involving trabeculectomy, ExPRESS and Ahmed valve implants.
Sheng Q; Zhai R; Sun Y; Fan X; Ying Y; Kong X
Graefes Arch Clin Exp Ophthalmol; 2023 Mar; 261(3):791-801. PubMed ID: 36303060
[TBL] [Abstract][Full Text] [Related]
4. 2% Ganciclovir Controlled Posner-Schlossman Syndrome Relapse and Reduced the Chance of Corticosteroid Dependence: A Large Cohort in East China.
Sheng Q; Sun Y; Zhai R; Fan X; Ying Y; Kong X
Ocul Immunol Inflamm; 2023 Jul; ():1-8. PubMed ID: 37437131
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes in cytomegalovirus-positive Posner-Schlossman syndrome patients treated with topical ganciclovir therapy.
Su CC; Hu FR; Wang TH; Huang JY; Yeh PT; Lin CP; Wang IJ
Am J Ophthalmol; 2014 Nov; 158(5):1024-1031.e2. PubMed ID: 25124264
[TBL] [Abstract][Full Text] [Related]
6. 2% Ganciclovir Eye Drops Control Posner-Schlossman Syndrome Relapses With/Without Cytomegalovirus Intraocular Reactivation.
Sheng Q; Zhai R; Fan X; Kong X
Front Med (Lausanne); 2022; 9():848820. PubMed ID: 35355609
[TBL] [Abstract][Full Text] [Related]
7. Features of hemodynamic and immunological parameters in patients with recurrent uveitis complicated by hypertension, Fuchs heterochromic uveitis and Posner-Schlossman syndrome.
Khramenko NI; Velychko LM; Konovalova NV; Bogdanova OV; Gheorghe LD; Bobescu DV
Rom J Ophthalmol; 2023; 67(1):20-32. PubMed ID: 37089809
[No Abstract] [Full Text] [Related]
8. The Analysis of Dynamic Changes and Prognosis of Posner-Schlossman Syndrome with Cytomegalovirus Infection and Antiviral Therapy.
Sheng Q; Zhai R; Fan X; Kong X
J Ophthalmol; 2021; 2021():6687929. PubMed ID: 34123414
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of cases needing advanced treatment for intractable Posner-Schlossman syndrome.
Maruyama K; Maruyama Y; Sugita S; Mori K; Yokoyama Y; Sanuki-Kunimatsu S; Nakagawa H; Kinoshita S; Mochizuki M; Nakazawa T
BMC Ophthalmol; 2017 Apr; 17(1):45. PubMed ID: 28399831
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics of virus-related uveitic secondary glaucoma: focus on cytomegalovirus and varicella zoster virus.
Fan X; Li Z; Zhai R; Sheng Q; Kong X
BMC Ophthalmol; 2022 Mar; 22(1):130. PubMed ID: 35317777
[TBL] [Abstract][Full Text] [Related]
11. Different composition of intraocular immune mediators in Posner-Schlossman-Syndrome and Fuchs' Uveitis.
Pohlmann D; Schlickeiser S; Metzner S; Lenglinger M; Winterhalter S; Pleyer U
PLoS One; 2018; 13(6):e0199301. PubMed ID: 29944680
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of macular microvascular density using optical coherence tomography angiography in patients with Posner-Schlossman syndrome.
Guo XJ; Chen D; Zhou LJ; Luo SK; Lu Y; Guo JJ
BMC Ophthalmol; 2022 Aug; 22(1):339. PubMed ID: 35948955
[TBL] [Abstract][Full Text] [Related]
13. Long-term oral therapy with valganciclovir in patients with Posner-Schlossman syndrome.
Sobolewska B; Deuter C; Doycheva D; Zierhut M
Graefes Arch Clin Exp Ophthalmol; 2014 Jan; 252(1):117-24. PubMed ID: 24287937
[TBL] [Abstract][Full Text] [Related]
14. Surgical Outcomes of Penetrating Canaloplasty in Patients with Uncontrolled Posner-Schlossman Syndrome: A Prospective Study.
Ye W; Fu L; Li J; Zhu S; Zhang S; Gu J; Jiang Y; Liang Y
Ocul Immunol Inflamm; 2023 Mar; ():1-7. PubMed ID: 36892932
[TBL] [Abstract][Full Text] [Related]
15. Posner-Schlossman Syndrome European Study Group: study protocol and baseline patients characteristics of a multicentre study.
Interlandi E; Cimino L; Accorinti M; Miserocchi E; Latanza L; Allegri P; Mora P; Fonollosa A; Adan A; Pavesio C; De Marco R; Gandolfi SA; Nucci P; De Luca M; Gozzi F; Visioli G; Rissotto F; Rissotto R; Bellucci C; Cachero JM; Pellegrini F; Li Calzi G; Sainz de la Maza M; Cirillo P; Mastrofilippo V; Sacchi M
Br J Ophthalmol; 2024 May; ():. PubMed ID: 38811053
[TBL] [Abstract][Full Text] [Related]
16. Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China.
Sheng Q; Sun Y; Zhai R; Fan X; Ying Y; Kong X
Front Public Health; 2022; 10():1051378. PubMed ID: 36711335
[TBL] [Abstract][Full Text] [Related]
17. Digital droplet polymerase chain reaction analysis of common viruses in the aqueous humour of patients with Posner-Schlossman syndrome in Chinese population.
Cao G; Tan C; Zhang Y; Kong X; Sun X; Ma Y; Chen J; Guan M
Clin Exp Ophthalmol; 2019 May; 47(4):513-520. PubMed ID: 30414235
[TBL] [Abstract][Full Text] [Related]
18. Posner-Schlossman syndrome in Wenzhou, China: a retrospective review study.
Jiang JH; Zhang SD; Dai ML; Yang JY; Xie YQ; Hu C; Mao GY; Lu F; Liang YB
Br J Ophthalmol; 2017 Dec; 101(12):1638-1642. PubMed ID: 28450379
[TBL] [Abstract][Full Text] [Related]
19. Construction of a mouse model of Posner-Schlossman syndrome by anterior chamber infection with cytomegalovirus.
Liu X; Wang H; Ma L; Ying M; Liu Q; Chang H; Jin S; Yang F; Zhu X; Sun X; Xu F; Liu H
Exp Eye Res; 2022 May; 218():109009. PubMed ID: 35276185
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
